Ehlers-Danlos Syndrome

1. Clinical Overview

Summary

Ehlers-Danlos Syndromes (EDS) comprise a clinically and genetically heterogeneous group of hereditary connective tissue disorders characterised by the classical triad of joint hypermobility, skin hyperextensibility, and tissue fragility. [1,2] The underlying pathology involves defects in collagen biosynthesis, structure, processing, or proteins interacting with collagen in the extracellular matrix. [3]

The 2017 International Classification recognises 13 distinct subtypes, each with specific clinical features and most with identified genetic mutations. [1] Hypermobile EDS (hEDS) represents the most common subtype, affecting approximately 1 in 5,000 individuals, though it remains the only subtype without an identified causative gene. [2] Classical EDS (cEDS) is characterised by marked skin hyperextensibility and atrophic scarring, caused by mutations in COL5A1 or COL5A2 genes affecting type V collagen. [4] Vascular EDS (vEDS) is the most severe subtype, caused by mutations in COL3A1 affecting type III collagen, with median survival of 51 years due to arterial, intestinal, and uterine rupture. [5,6]

Management is predominantly supportive and multidisciplinary, centred on physiotherapy for joint stabilisation, pain management, and surveillance for subtype-specific complications. [7] Celiprolol has demonstrated efficacy in reducing arterial complications in vEDS. [8] Genetic counselling is essential for all subtypes given the heritable nature and implications for family planning. Early diagnosis in childhood is critical to implement protective strategies and prevent cumulative joint damage before skeletal maturity. [9]

Key Facts

Clinical Pearls

The "5 Ps" of EDS Recognition: Pain (chronic, diffuse), Poor wound healing (atrophic scars), Prolapse (mitral valve, pelvic organs), Party tricks (joint hypermobility demonstrations), Prone to bruising (often unexplained, extensive). This mnemonic captures the multisystem nature of these disorders.

Vascular EDS Recognition Triad: Thin, translucent skin with visible subcutaneous venous pattern + characteristic facial features (thin lips, small chin, prominent eyes, lobeless ears) + family history of arterial rupture or unexplained death before age 50. Any child with this constellation requires urgent genetic evaluation. [5]

Beighton Score Caution: A positive Beighton score indicates generalised joint hypermobility but does NOT diagnose EDS. Many children are hypermobile without pathology (estimated 10-30% of school-age children). The distinction lies in associated symptoms: chronic pain, recurrent dislocations, skin changes, delayed motor milestones, and positive family history. [10]

The "Party Trick" Warning: Children with hEDS often demonstrate remarkable flexibility that they may show as "party tricks." While initially appearing benign, repeated hypermobile movements cause cumulative microtrauma, accelerating joint degeneration. Early recognition and activity modification are protective.

Diagnostic Delay Reality: Mean diagnostic delay for EDS is 10-12 years, with patients seeing an average of 5-10 specialists before diagnosis. [11] In children, presentations to orthopaedics (recurrent dislocations), dermatology (unusual scarring), haematology (bruising), and rheumatology (joint pain) may all precede diagnosis.

Why This Matters Clinically

Ehlers-Danlos Syndromes represent an important differential diagnosis in paediatric practice for several critical reasons:

Diagnostic Importance: Children with EDS often present to multiple specialties with seemingly unrelated complaints before the unifying diagnosis is made. Recognition of the characteristic phenotype prevents unnecessary investigations, avoids inappropriate treatments, and enables appropriate genetic counselling and family screening.

Safety Implications: Identification of vascular EDS is life-saving, as this subtype carries substantial mortality risk from arterial and organ rupture. Children with vEDS require avoidance of contact sports, careful planning for any surgical procedures, and specific medical management with celiprolol. Failure to recognise vEDS before an invasive procedure can be catastrophic.

Developmental Impact: Early diagnosis in childhood allows implementation of protective strategies during the critical period of skeletal development. Appropriate physiotherapy can strengthen periarticular musculature to compensate for ligamentous laxity, potentially preventing the progressive joint damage and chronic pain that characterise untreated adult disease.

Psychological Considerations: Children with EDS frequently experience years of unexplained symptoms that may be dismissed or attributed to "growing pains" or psychological factors. The relief of diagnosis and appropriate management significantly improves quality of life and prevents development of chronic pain behaviours.

---

2. Epidemiology

Incidence & Prevalence

The true prevalence of Ehlers-Danlos Syndromes is difficult to establish due to historical classification changes, variable clinical expression, and substantial underdiagnosis, particularly for milder phenotypes. [2]

Temporal Trends: Reported prevalence has increased substantially over the past two decades, reflecting improved awareness and diagnostic criteria rather than true incidence increase. The 2017 revised criteria for hEDS are more stringent than previous classifications, which may affect future prevalence estimates.

Demographics

Risk Factors

Non-Modifiable Factors:

Modifiable Factors:

---

3. Pathophysiology

Molecular Basis of Connective Tissue Dysfunction

Step 1: Genetic Mutation

The Ehlers-Danlos Syndromes result from mutations in genes encoding collagens, collagen-modifying enzymes, or proteins involved in extracellular matrix assembly. [3,4] Different genetic defects produce distinct clinical phenotypes:

Step 2: Abnormal Collagen Production and Structure

Collagen represents the most abundant protein in the human body (25-30% of total protein content), providing structural support to skin, bones, blood vessels, and internal organs. [3] Normal collagen biosynthesis involves:

1. Transcription and Translation: Procollagen chains synthesised in rough endoplasmic reticulum
2. Post-translational Modification: Hydroxylation of proline and lysine residues (requires vitamin C, Fe²⁺, lysyl hydroxylase)
3. Triple Helix Formation: Three procollagen chains wind into characteristic triple helix
4. Secretion and Processing: Procollagen secreted, N- and C-propeptides cleaved
5. Fibril Assembly: Tropocollagen molecules assemble into fibrils, then fibres
6. Cross-linking: Lysyl oxidase catalyses covalent cross-links for tensile strength

Exam Detail: Collagen Types and Tissue Distribution:

Glycine-X-Y Repeat: Collagen's characteristic Gly-X-Y triplet repeat allows tight triple helix formation. Glycine (smallest amino acid) must occupy every third position to fit in the helix centre. Glycine substitution mutations cause protein misfolding and disease severity often correlates with substitution position along the helix.

Dominant Negative Effect: Many EDS mutations (particularly in vEDS) exert a dominant negative effect—mutant chains incorporate into triple helices with normal chains, rendering the entire molecule dysfunctional. This explains why heterozygous mutations cause disease despite presence of one normal allele.

Step 3: Tissue Fragility and Clinical Manifestations

Defective collagen leads to widespread connective tissue dysfunction:

Classification Systems

2017 International Classification (13 Subtypes)

The 2017 International Classification represents the current standard, replacing the 1997 Villefranche nosology. [1] It recognises 13 distinct subtypes based on clinical features and genetic/biochemical findings:

Major Subtypes (Most Clinically Relevant):

Rare Subtypes:

Beighton Score (Hypermobility Assessment)

The Beighton Score is the standard clinical tool for assessing generalised joint hypermobility. [10] It evaluates 9 points across 5 manoeuvres:

Interpretation (Age-Adjusted):

Critical Caveat: The Beighton Score assesses hypermobility but does NOT diagnose EDS. Many children meet hypermobility criteria without having a connective tissue disorder. Diagnosis requires additional clinical features and, for most subtypes, genetic confirmation.

5-Point Questionnaire (Historical Hypermobility)

When current Beighton score is negative but historical hypermobility suspected:

1. Can you now (or could you ever) place your hands flat on the floor without bending your knees?
2. Can you now (or could you ever) bend your thumb to touch your forearm?
3. As a child, did you amuse your friends by contorting your body into strange shapes or could you do the splits?
4. As a child or teenager, did your shoulder or kneecap dislocate on more than one occasion?
5. Do you consider yourself "double-jointed"?

Interpretation: ≥2 positive answers suggests historical hypermobility and contributes to hEDS criteria when current Beighton score is 1 point below threshold.

---

4. Clinical Presentation

Age-Specific Presentations in Childhood

Symptoms by System

Musculoskeletal (Present in >90% of patients):

Cutaneous:

Cardiovascular:

Gastrointestinal:

Neurological and Autonomic:

Ocular:

Physical Signs

General Inspection:

• Marfanoid habitus (tall, thin) in some subtypes
• Characteristic facial features in vEDS: thin lips, small chin, lobeless ears, prominent eyes
• Visible subcutaneous venous pattern (vEDS)
• May appear younger than stated age (smooth, unwrinkled skin)

Skin Examination:

Musculoskeletal Examination:

• Complete Beighton score assessment
• Joint stability testing (drawer tests, apprehension signs)
• Pes planus (flat feet)—common and contributes to gait instability
• Scoliosis assessment (forward bend test)
• Genu recurvatum (knee hyperextension)
• Evidence of previous dislocations (joint deformity, crepitus)

Red Flags Requiring Urgent Action

[!CAUTION] LIFE-THREATENING RED FLAGS — Immediate Assessment Required:

Vascular Emergency (vEDS):

• Sudden severe chest, abdominal, or flank pain (arterial rupture/dissection)
• Signs of stroke in young patient (carotid/vertebral dissection)
• Acute abdomen with minimal trauma (bowel perforation)
• Haemoptysis or sudden dyspnoea (pulmonary artery rupture)
• Postpartum collapse (uterine rupture)
• Any new significant pain in known vEDS patient

Other Emergencies:

• Acute vision loss (retinal detachment in kEDS)
• Neurological symptoms with neck pain (cervical instability)
• Acute respiratory distress (pneumothorax in kEDS, severe scoliosis)

---

5. Investigations

Diagnostic Approach

Principle: Diagnosis of EDS is primarily clinical, using established diagnostic criteria. Genetic testing confirms specific subtypes (except hEDS, which has no known gene). [1,2] Laboratory tests are useful to exclude other diagnoses and assess for complications.

First-Line Investigations (Bedside)

Laboratory Investigations

Genetic Testing Considerations:

Imaging Investigations

Diagnostic Criteria

2017 Criteria for Hypermobile EDS (hEDS)

The diagnosis of hEDS requires ALL THREE criteria: [2]

Criterion 1 — Generalised Joint Hypermobility (GJH):

• Beighton Score ≥6/9 (pre-pubertal children)
• Beighton Score ≥5/9 (post-pubertal to age 50)
• Beighton Score ≥4/9 (age >50)
• If Beighton 1 below threshold: positive 5-point questionnaire (≥2 yes) can count

Criterion 2 — Two or More of Features A, B, C (A requires 5+ features):

Feature A (Systemic Manifestations — must have ≥5):

• Unusually soft or velvety skin
• Mild skin hyperextensibility
• Unexplained striae (distensae or rubrae)
• Bilateral piezogenic papules
• Recurrent or multiple abdominal herniae
• Atrophic scarring (non-papyraceous) at ≥2 sites
• Pelvic floor, rectal, or uterine prolapse without predisposing factors
• Dental crowding AND high/narrow palate
• Arachnodactyly (positive wrist OR thumb sign)
• Arm span:height ratio ≥1.05
• MVP (mild, by strict echo criteria)
• Aortic root dilation (Z-score >+2)

Feature B (Positive Family History):

• One or more first-degree relatives independently meeting hEDS criteria

Feature C (Musculoskeletal Complications):

• Chronic musculoskeletal pain (≥3 months) in ≥2 limbs
• Recurrent joint dislocations OR frank joint instability

Criterion 3 — Prerequisites (ALL must be met):

1. Absence of unusual skin fragility (suggests other EDS)
2. Exclusion of other heritable CTDs (Marfan, Loeys-Dietz, other EDS)
3. Exclusion of alternative diagnoses (rheumatoid, lupus, etc.)

Exam Detail: Distinguishing Features Between Major EDS Subtypes:

Differential Diagnosis

---

6. Management

Principles of Management

Management of EDS is primarily supportive, multidisciplinary, and lifelong. [7,9] Key principles:

1. No curative treatment exists — management focuses on symptom control and complication prevention
2. Physiotherapy is central — strengthening periarticular muscles compensates for ligamentous laxity
3. Subtype-specific management — vEDS requires specific precautions and medical therapy
4. Multidisciplinary approach essential — genetics, rheumatology, physiotherapy, psychology, cardiology, pain medicine
5. Education and self-management — patients and families must understand the condition

Management Algorithm

┌─────────────────────────────────────────────────────────────────────────┐
│                    SUSPECTED EDS IN CHILD                               │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│  ┌─────────────────┐                                                   │
│  │ Clinical        │                                                   │
│  │ Assessment      │──────────────────────────────────────────────────┐│
│  │ • Beighton      │                                                  ││
│  │ • Skin features │                                                  ││
│  │ • Family Hx     │                                                  ││
│  │ • Red flags     │                                                  ││
│  └────────┬────────┘                                                  ││
│           │                                                           ││
│           ▼                                                           ││
│  ┌─────────────────────────────────────────────────────────────────┐  ││
│  │ VASCULAR EDS FEATURES?                                          │  ││
│  │ Thin translucent skin, visible veins, facies, FHx rupture      │  ││
│  └──────────────────────────────────────────┬──────────────────────┘  ││
│                                              │                         ││
│                     ┌────────────────────────┼────────────────────┐   ││
│                     │                        │                    │   ││
│                  YES▼                      NO▼                    │   ││
│  ┌─────────────────────────┐  ┌─────────────────────────────────┐│   ││
│  │ URGENT GENETICS REFERRAL│  │ Apply 2017 hEDS/cEDS Criteria  ││   ││
│  │ • COL3A1 testing        │  │ Consider genetic testing       ││   ││
│  │ • Avoid invasive tests  │  │ if features suggest specific   ││   ││
│  │ • Activity restriction  │  │ subtype                        ││   ││
│  │ • Start celiprolol      │  └────────────────┬────────────────┘│   ││
│  │   if confirmed          │                   │                  │   ││
│  └─────────────────────────┘                   │                  │   ││
│                                                 │                  │   ││
│                                                 ▼                  │   ││
│                              ┌────────────────────────────────────┐│   ││
│                              │ MULTIDISCIPLINARY MANAGEMENT       ││   ││
│                              │ • Physiotherapy                    ││   ││
│                              │ • Pain management                  ││   ││
│                              │ • Psychological support            ││   ││
│                              │ • Cardiac surveillance             ││   ││
│                              │ • Genetic counselling              ││   ││
│                              │ • Activity modification            ││   ││
│                              │ • School accommodations            ││   ││
│                              └────────────────────────────────────┘│   ││
└─────────────────────────────────────────────────────────────────────────┘

Conservative Management

Physiotherapy (Central to Management): [7,13]

Key Principles:

• Closed-chain exercises preferred (feet on ground)
• Avoid end-range joint positions
• Progress slowly to avoid flares
• Hydrotherapy excellent (reduces joint loading)
• Avoid high-impact activities (running, jumping)

Lifestyle Modifications:

Assistive Devices:

Medical Management

Pain Management: [7]

Management of POTS/Dysautonomia: [12]

Vascular EDS Specific Medical Management: [8]

Clinical Pearl: Celiprolol in Vascular EDS: The landmark Ong et al. trial (2010) randomised 53 vEDS patients to celiprolol vs observation. Celiprolol group had 68% relative risk reduction in arterial events (p=0.04). [8] This is the only medical therapy with RCT evidence in EDS. Celiprolol is a β1-blocker with β2-agonist properties, which may reduce arterial wall stress while avoiding vasoconstriction.

Surgical Considerations

General Principles for Surgery in EDS:

Vascular EDS Surgery: [5,14]

[!CAUTION] Surgery in vEDS is HIGH RISK:

• 50% perioperative complication rate reported
• Only proceed for life-threatening indications
• Endovascular approach preferred when possible
• Specialist centre essential
• Avoid elective surgery if at all possible

Orthopaedic Surgery:

Psychological Support

Psychological morbidity is common in EDS due to chronic pain, diagnostic delay, and functional limitations: [15]

Key Interventions:

• Cognitive Behavioural Therapy (CBT) for pain management and anxiety
• Acceptance and Commitment Therapy (ACT)
• Peer support groups (e.g., EDS societies)
• Family therapy where indicated
• School liaison for educational support

Genetic Counselling

Follow-Up and Surveillance

---

7. Complications

Immediate Complications (Hours to Days)

Early Complications (Weeks to Months)

Late Complications (Years)

Pregnancy Complications (Maternal)

---

8. Prognosis & Outcomes

Natural History by Subtype

Outcomes with Treatment

Prognostic Factors

Favourable Factors:

Unfavourable Factors:

Functional Outcomes in Childhood

---

9. Viva Scenarios & Examination Focus

Common Exam Questions

1. "A 10-year-old presents with recurrent shoulder dislocations and widespread joint pain. What is your approach?"
2. "How do you differentiate Ehlers-Danlos Syndrome from Marfan Syndrome?"
3. "Describe the Beighton Score and its limitations"
4. "A child with vascular EDS needs surgery. What are your considerations?"
5. "What is the genetic basis of the main EDS subtypes?"
6. "How would you counsel a family following diagnosis of vascular EDS?"

Viva Points

Viva Point: Opening Statement: "Ehlers-Danlos Syndromes are a heterogeneous group of heritable connective tissue disorders caused by defects in collagen or collagen-related proteins, characterised by the triad of joint hypermobility, skin hyperextensibility, and tissue fragility. The 2017 classification recognises 13 subtypes, with hypermobile EDS being most common and vascular EDS being most severe."

Key Facts to Deliver:

• Prevalence: 1 in 5,000-20,000
• hEDS: no known gene mutation; diagnosis clinical (2017 criteria)
• vEDS: COL3A1 mutation; median survival 51 years; arterial/organ rupture
• cEDS: COL5A1/A2; marked skin hyperextensibility, atrophic scarring
• Beighton Score: ≥6/9 positive in children (assesses hypermobility, not diagnosis)
• Treatment: Physiotherapy central; celiprolol for vEDS (68% reduction in arterial events, Ong 2010)

Model Answer: Child with Suspected EDS

Question: "A 12-year-old girl presents with widespread joint pain, fatigue, and has dislocated her patella twice. How would you assess and manage her?"

Model Answer: "I would approach this systematically, considering Ehlers-Danlos Syndrome as an important differential for this presentation.

History: I would explore her joint symptoms in detail—onset, distribution, any triggering factors. I would ask specifically about joint hypermobility ("party tricks"), bruising, skin quality, wound healing, and family history of hypermobility or joint problems. I would enquire about fatigue, POTS symptoms (dizziness on standing), and gastrointestinal symptoms.

Examination: I would perform a comprehensive examination including:

• Beighton Score (9-point assessment of hypermobility)
• Skin assessment (hyperextensibility, texture, scarring, bruising)
• Full joint examination looking for instability
• Cardiovascular examination including postural blood pressure
• Looking for features suggesting a specific subtype, particularly vEDS red flags

Differential Diagnosis: Key differentials include hypermobile EDS (most likely), benign joint hypermobility syndrome, other EDS subtypes, Marfan syndrome, Loeys-Dietz syndrome, and juvenile idiopathic arthritis.

Investigations: I would arrange:

• Baseline echocardiogram (all EDS)
• Inflammatory markers to exclude JIA
• Genetic testing if clinical features suggest cEDS or vEDS

Management: If hEDS is confirmed clinically:

• Refer to physiotherapy for joint stabilisation programme (cornerstone of management)
• Pain management with simple analgesia, considering low-dose amitriptyline for chronic pain
• Activity modification advice—avoid high-impact sports, contact sports, overstretching
• School accommodations as needed
• Referral to genetics for formal assessment and family counselling
• Psychology input for chronic pain management
• Regular follow-up with paediatric rheumatology

I would emphasise to the family that while hEDS is lifelong and has no cure, proactive management can significantly improve quality of life and prevent progression."

Common Mistakes in Exams

❌ Mistakes That Lose Marks:

---

10. Prevention & Screening

Primary Prevention

There is no primary prevention for EDS as these are genetic conditions. However:

Secondary Prevention (Complication Prevention)

Screening Recommendations

---

11. Patient & Family Information

What is Ehlers-Danlos Syndrome?

Ehlers-Danlos Syndrome (EDS) is the name for a group of inherited conditions that affect the connective tissue in your body. Connective tissue is like the "glue" that holds everything together—it's in your skin, joints, blood vessels, and organs.

In EDS, there's a problem with how this connective tissue is made, usually because of a change (mutation) in a gene that provides instructions for making a protein called collagen. This means:

• Your joints may be extra flexible (hypermobile) and may dislocate easily
• Your skin may be stretchy, soft, and bruise easily
• You may heal more slowly from cuts and have unusual scars

There are different types of EDS. The most common type (hypermobile EDS) mainly affects joints and causes pain, but isn't dangerous to your health. A rarer type (vascular EDS) is more serious because it affects blood vessels.

Is It Serious?

For most children with EDS, the condition is not life-threatening but can significantly affect daily life because of:

• Joint pain and tiredness
• Frequent injuries or dislocations
• Difficulty with handwriting or physical activities

The vascular type (vEDS) is more serious and needs careful monitoring by specialists.

How Is It Treated?

The most important treatment is physiotherapy:

• Special exercises to strengthen the muscles around your joints
• This helps protect joints from dislocating
• Your physiotherapist will design a safe exercise programme

Other treatments include:

• Pain relief medications when needed
• Splints or supports for unstable joints
• Making changes at school (extra time, using a laptop)
• Learning to pace activities to manage tiredness

There is no cure, but treatment helps manage symptoms and prevent complications.

Living with EDS

When to Seek Urgent Help

Go to A&E or call 999 if:

• Sudden severe chest, tummy, or back pain
• Signs of stroke (face drooping, arm weakness, difficulty speaking)
• A joint dislocation that won't go back in
• Severe injury or heavy bleeding

See your doctor soon if:

• You have a new joint that keeps dislocating
• Your pain is getting worse despite treatment
• You feel very dizzy when standing up
• You're finding it hard to cope emotionally

Family and Genetic Counselling

EDS is inherited (runs in families). If one parent has EDS, each child has a 50% chance of inheriting it. Your family will be offered genetic counselling to:

• Explain how EDS is passed on
• Discuss whether other family members should be tested
• Talk about options for future pregnancies if you wish

---

12. References

Primary Classification & Diagnostic Criteria

1. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26. doi:10.1002/ajmg.c.31552

2. Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history. Am J Med Genet C Semin Med Genet. 2017;175(1):48-69. doi:10.1002/ajmg.c.31538

Genetic & Molecular Basis

3. Mao JR, Bristow J. The Ehlers-Danlos syndrome: on beyond collagens. J Clin Invest. 2001;107(9):1063-1069. doi:10.1172/JCI12881

4. Symoens S, Syx D, Malfait F, et al. Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria. Hum Mutat. 2012;33(10):1485-1493. doi:10.1002/humu.22137

Vascular EDS

5. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673-680. doi:10.1056/NEJM200003093421001

6. Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40-47. doi:10.1002/ajmg.c.31553

Management & Treatment

7. Castori M, Tinkle B, Levy H, et al. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017;175(1):148-157. doi:10.1002/ajmg.c.31539

8. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376(9751):1476-1484. doi:10.1016/S0140-6736(10)60960-9

9. Engelbert RH, Juul-Kristensen B, Pacey V, et al. The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):158-167. doi:10.1002/ajmg.c.31545

Clinical Assessment

10. Smits-Engelsman B, Klerks M, Kirby A. Beighton score: a valid measure for generalized hypermobility in children. J Pediatr. 2011;158(1):119-123. doi:10.1016/j.jpeds.2010.07.021

11. Berglund B, Pettersson C, Pigg M, Kristiansson P. Self-reported quality of life, anxiety and depression in individuals with Ehlers-Danlos syndrome (EDS): a questionnaire study. BMC Musculoskelet Disord. 2015;16:89. doi:10.1186/s12891-015-0549-7

Dysautonomia & Comorbidities

12. Roma M, Marden CL, De Wandele I, et al. Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. Auton Neurosci. 2018;215:89-96. doi:10.1016/j.autneu.2018.02.006

13. Russek LN, Stott P, Simmonds J. Recognizing and effectively managing hypermobility-related conditions. Phys Ther. 2019;99(9):1189-1200. doi:10.1093/ptj/pzz078

Complications & Prognosis

14. Oderich GS, Panneton JM, Bower TC, et al. The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg. 2005;42(1):98-106. doi:10.1016/j.jvs.2005.03.053

15. Baeza-Velasco C, Bourdon C, Montalescot L, et al. Low- and high-anxious hypermobile Ehlers-Danlos syndrome patients: comparison of psychosocial and health variables. Rheumatol Int. 2018;38(5):871-878. doi:10.1007/s00296-018-4003-7

Paediatric-Specific

16. Engelbert RH, Bank RA, Sakkers RJ, et al. Pediatric generalized joint hypermobility with and without musculoskeletal complaints: a localized or systemic disorder? Pediatrics. 2003;111(3):e248-e254. doi:10.1542/peds.111.3.e248

17. Scheper MC, de Vries JE, Verbunt J, Engelbert RH. Chronic pain in hypermobility syndrome and Ehlers-Danlos syndrome (hypermobility type): it is a challenge. J Pain Res. 2015;8:591-601. doi:10.2147/JPR.S64251

Kyphoscoliotic & Rare Subtypes

18. Yeowell HN, Steinmann B. PLOD1-Related Kyphoscoliotic Ehlers-Danlos Syndrome. In: Adam MP, et al., eds. GeneReviews. Seattle (WA): University of Washington, Seattle; 2000 [updated 2018]. PMID:20301555

19. Ritelli M, Dordoni C, Venturini M, et al. Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations. Orphanet J Rare Dis. 2013;8:58. doi:10.1186/1750-1172-8-58

Guidelines & Consensus

20. Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):212-219. doi:10.1002/ajmg.c.31554

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Ehlers-Danlos Syndromes are complex conditions requiring specialist multidisciplinary input. Always consult qualified healthcare professionals for individual patient assessment and management decisions. Emergency presentations in vascular EDS require immediate specialist intervention.

---